Mounjaro (tirzepatide) : Lilly's dual GIP/GLP-1 agonist has delivered best-in-class weight loss and glycemic control in T2D and, under its obesity brand Zepbound , has outperformed semaglutide in head ...

Many Mounjaro users have considered making the swap after Eli Lilly announced prices would be increasing in the UK by 170 percent ...

Twice as many employers as last year say they are planning to pull back on filling jobs, according to a new Conference Board survey.

Patients' vision loss, which is rare according to a new study, is also the subject of multiple lawsuits, including two filed ...

COPENHAGEN (Reuters) -As Novo Nordisk's sales of its blockbuster weight-loss drug Wegovy boomed, the Danish drugmaker raced to expand manufacturing capacity and sales outreach with a hiring spree that ...

The pharma giant has almost doubled the size of its workforce over the last five years but is now looking to tighten cost ...

As Novo Nordisk's sales of its blockbuster weight-loss drug Wegovy boomed, the Danish drugmaker raced to expand manufacturing capacity and sales outreach with a hiring spree that almost doubled staff ...

Multiple lawsuits have been filed against the makers of the popular weight-loss drug. Litigants cite blindness and other side-effects.

A rumor that pharmaceutical companies behind popular weight-loss and diabetes medications like Ozempic faced lawsuits totaling more than $2 billion circulated online in August 2025.

Worker-led protests erupted at Microsoft headquarters this week as the tech company promises an “urgent” review of the ...

The U.S. Food and Drug Administration (FDA) has approved Novo Nordisk's popular weight-loss drug Wegovy to treat a serious ...